Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.

Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer treatment reviews Pubmed

Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.

Cancer treatment reviews , Volume 30 (6): -574 – Sep 16, 2004

Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.

Cancer treatment reviews , Volume 30 (6): -574 – Sep 16, 2004

Loading next page...
 
/lp/pubmed/switching-to-exemestane-after-2-3-years-of-adjuvant-tamoxifen-prolongs-dpWJ998FP1

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0305-7372
DOI
10.1016/j.ctrv.2004.06.005
pmid
15325038

Abstract

Journal

Cancer treatment reviewsPubmed

Published: Sep 16, 2004

References